Cancer drug duvelisib tested to prevent lymphoma return after transplant
NCT ID NCT04331119
First seen Jan 05, 2026 · Last updated Jun 24, 2026 · Updated 31 times
Summary
This phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after autologous stem cell transplant in 17 adults with T-cell lymphoma. The goal was to see if duvelisib is safe and helps keep the cancer from coming back. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
duvelisib (Copiktra)
What this could lead to
If it works, this could point toward a way to keep T-cell lymphoma from coming back after a stem cell transplant.
What could go wrong
This trial was terminated early with only 17 participants, so results are very limited. Duvelisib may cause side effects and may not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.